Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an in vivo study

被引:23
作者
Al-Hallak, M. H. D. Kamal [1 ,2 ]
Sarfraz, Muhammad K. [1 ,3 ]
Azarmi, Shirzad [1 ,4 ]
Roa, Wilson H. [5 ]
Finlay, Warren H. [6 ]
Rouleau, Claude [7 ]
Lobenberg, Raimar [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
[2] Damascus Univ, Fac Pharm, Damascus, Syria
[3] Islamia Univ Bahawalpur, Fac Pharm & Alternat Med, Bahawalpur, Pakistan
[4] Tabriz Univ Med Sci, Fac Pharm, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[5] Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada
[6] Univ Alberta, Dept Mech Engn, Edmonton, AB T6G 2G8, Canada
[7] Fisheries & Oceans Canada, Maurice Lamontagne Inst, Mont Joli, PQ G5H 3Z4, Canada
关键词
D O I
10.4155/TDE.12.42
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Background: Effervescent inhalable nanoparticles (NPs) have previously been shown to be a promising alternative to conventional lung cancer treatment in animals. This study investigates the biodistribution of effervescent inhalable NPs after a single dose administration via pulmonary route in lung cancer-bearing mice. Methods & results: Whole-body autoradiography and confocal laser-scanning microscopy (CLSM) were used to investigate the distribution of inhalable NPs loaded in an effervescent microcarrier. Inhalable doxorubicin-loaded NPs were tagged with 14C for whole-body autoradiography, or with fluorescein isothiocyanate for CLSM imaging. After pulmonary delivery, NPs were widely disseminated in the lungs with a long retention time (24 h). The heart was radioactivity free at all time points of the study. CLSM images showed that inhalable NPs were taken up by cells and that doxorubicin was released to the cell nuclei. Conclusion: This is the first study to investigate the distribution of inhalable NPs in a lung cancer-bearing animal model. Inhalable NPs achieved deep lung deposition, were actively released from microcarrier particles, spread to different parts of the lung and released doxorubicin in vivo. These NP characteristics contribute to the efficacy of effervescent inhalable NPs as a lung cancer treatment.
引用
收藏
页码:725 / 734
页数:10
相关论文
共 42 条
[1]
Al-Hallak KM, 2010, EUR J PHARM BIOPHARM, V76, P112
[2]
Pulmonary delivery of inhalable nanoparticles: dry powder inhalers [J].
Al-Hallak, M. H. D. Kamal ;
Sarfraz, Muhammad Khan ;
Azarmi, Shirzad ;
Roa, Wilson H. ;
Finlay, Warren H. ;
Lobenberg, Raimar .
THERAPEUTIC DELIVERY, 2011, 2 (10) :1313-1324
[3]
Microcalorimetric Method to Assess Phagocytosis: Macrophage-Nanoparticle Interactions [J].
Al-Hallak, M. H. D. Kamal ;
Sarfraz, Muhammad Khan ;
Azarmi, Shirzad ;
Kohan, M. H. Gilzad ;
Roa, Wilson H. ;
Loebenberg, Raimar .
AAPS JOURNAL, 2011, 13 (01) :20-29
[4]
Pulmonary Toxicity of Polysorbate-80-coated Inhalable Nanoparticles; In vitro and In vivo Evaluation [J].
Al-Hallak, M. H. D. Kamal ;
Azarmi, Shirzad ;
Sun, Chris ;
Lai, Patrick ;
Prenner, Elmar J. ;
Roa, Wilson H. ;
Loebenberg, Raimar .
AAPS JOURNAL, 2010, 12 (03) :294-299
[5]
Azarmi S, 2008, DRUG DEV IND PHARM, V34, P943, DOI [10.1080/03639040802149079, 10.1080/03639040802149079 ]
[6]
Targeted delivery of nanoparticles for the treatment of lung diseases [J].
Azarmi, Shirzad ;
Roa, Wilson H. ;
Loebenberg, Raimar .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (08) :863-875
[7]
Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles [J].
Azarmi, Shirzad ;
Tao, Xia ;
Chen, Hua ;
Wang, Zhaolin ;
Finlay, Warren H. ;
Lobenberg, Raimar ;
Roa, Wilson H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 319 (1-2) :155-161
[8]
Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers [J].
Calvo, P ;
VilaJato, JL ;
Alonso, MJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (05) :530-536
[9]
Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: Effect of freeze-drying adjuvants [J].
Cheow, Wean Sin ;
Ng, Mabel Li Ling ;
Kho, Katherine ;
Hadinoto, Kunn .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 404 (1-2) :289-300
[10]
FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets [J].
Cohen, MH ;
Williams, GA ;
Sridhara, R ;
Chen, G ;
Pazdur, R .
ONCOLOGIST, 2003, 8 (04) :303-306